Baker Bros. Advisors LP 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 255,361 9.900% |
53,581 (+26.55%) |
Filing |
| 2022-02-10 5:03 pm Purchase |
2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 201,779 9.900% |
5,732 (+2.92%) |
Filing |
| 2021-03-19 4:07 pm Purchase |
2021-03-16 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 196,048 9.900% |
346 (+0.18%) |
Filing |
| 2021-03-05 5:17 pm Unchanged |
2021-02-23 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 195,701 9.900% |
0 (Unchanged) |
Filing |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 195,701 9.900% |
127,157 (+185.51%) |
Filing |